Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $278.00. The ...
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.
BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.
Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...
1d
Hosted on MSNBecton Dickinson (BDX) Tops Q1 Earnings and Revenue EstimatesBecton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago. These ...
Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results